A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness ...

Activase (Alteplase) Market Report 2025 The Business Research Company's Global Activase Alteplase Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, And Emerging Trends I... ...

Summary. Stroke is the leading cause of disability in the elderly, and i.v. alteplase (recombinant tissue plasminogen activator) is the only Food and Drug Administration (FDA)-approved ...

Essity is unveiling the 'world’s first' tissue machine running entirely on geothermal steam at its Kawerau paper mill. Photo / Supplied The “world’s first” tissue machine operating ...

TAMPA, Fla. (WFLA)— A new nonstop flight from Tampa to Key West will begin in June, Breeze Airways announced. Beginning on June 12, 2025, flights will operate four times a week on Sundays ...

The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a ...